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Abstract
Background—Serum cartilage oligomeric matrix protein (sCOMP) is a biomarker for cartilage
degradation. Patient reported outcomes (PRO) are used to document post-injury recovery and may
be used to prospectively identify changes in the course of a season. It is unknown what effect
intense, continuous physical activity has on sCOMP levels and PRO values in athletes over the
duration of a soccer season.
Hypothesis/Purpose—The purpose of this study was to longitudinally document sCOMP
levels, and to determine if changes in PROs occur in collegiate soccer athletes during a season.
The hypotheses tested were that sCOMP levels and PRO scores would remain stable over the
duration of the spring soccer season.
Study Design—Case series; Level of evidence, 4.
Methods—29 NCAA Division-I soccer athletes (18 males, 11 females, age:19.6±1.2 years,
height:177.8±7.4cm, mass:73.8±10.2kg) participated in three[pre-(T1), mid-(T2), and post-
season(T3)] data collection sessions. Subjects were included if they participated in the spring
soccer season and were free of severe knee injury at the time of data collection. At each session
subjects completed PROs (Lysholm, IKDC) before serum collection.
The study was performed at the University of Kentucky.
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Results—For sCOMP(ng/mL) there was a significant effect for time with significant increases at
T2(1723.5±257.9, p<0.0001) and T3(1624.7±231.6, p=0.002) when compared with
T1(1482.9±217.9). For each of the PROs there was a significant effect for time with increases
from T1-T2 and T2-T3.
Conclusions—These data indicate sCOMP levels increased as athletes reported an increased
level of function over time. However, the differences in sCOMP levels did not reach the calculated
MDC value and the differences in PRO scores did not reach previously calculated MDC values. It
is unclear if these increases in sCOMP levels were due to an increase in cartilage matrix
breakdown or turnover. Even though these elevations may not be clinically meaningful, this
biomarker may have the potential to be used for future research studies investigating the effects of
exercise on overall joint health in longitudinal studies. In addition, these results indicate
fluctuations in sCOMP occur during a competitive season and must be taken into consideration for
future biomarker studies.
Key Terms
articular cartilage; biomarkers; soccer; cartilage matrix
INTRODUCTION
Primary osteoarthritis (OA) is characterized by irreversible joint destruction such as
cartilage degradation, osteophyte formation, and joint space narrowing39, and causes pain,
loss of function, activity limitations, and participation restrictions in the millions of
individuals it affects each year.1, 5, 11, 12, 40 It has been theorized that continuous and intense
physical activity can cause the development of primary OA in elite athletes.6, 25 In addition,
there has been speculation regarding how articular cartilage responds to increases in activity
level and determination of the levels related to articular cartilage damage due to intense
physical activity is unclear.14 It has been hypothesized that sports that include rapid
acceleration and deceleration moments, continuous training where the joints sustain high
impact, and athletes that compete at elite levels for an extended period of time are at an
increased risk of developing OA.6, 37 However, it is unknown as to the exact amount, types,
and intensity of exercise that is detrimental to the articular cartilage in the human joint.14, 37
At this time there are limited tools available to prospectively investigate the relationship
between early stages of degenerative joint disease, such as articular cartilage degradation,
and athletic participation.
Described as an instrument to measure the progress of a disease or the effect of a treatment
on disease progression29, biomarkers may serve as a tool to elucidate the effects of exercise
on articular cartilage and the eventual development of primary OA.33 A biomarker for
cartilage degradation, known as serum cartilage oligomeric matrix protein (sCOMP), has
been shown to be elevated after intense exercise.23, 33 Serum COMP is a non-collagenous
protein identified in synovium, ligamentous tissue, tendon, meniscus, and primarily articular
cartilage.7, 9, 13, 16, 30, 35, 36 Serum COMP levels are elevated after intense exercise,23, 33 and
are elevated in subjects who participated in less strenuous forms of physical
activity. 31, 32, 34 This indicates that exercise stresses the articular cartilage. However, the
balance of cartilage turnover caused by exercise and that which may cause long term
ramifications is unknown.14
Several studies have investigated changes in sCOMP during exercise. For example, in
healthy subjects who participated in moderate walking exercises, marathons, and ultra-
marathons, there was an increase in sCOMP levels after activity.23, 32, 33 Serum COMP
levels have been documented to return to baseline levels 30 minutes after a moderate
walking exercise and a longer period of time for more intense exercise.23, 32, 33 After a
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marathon, sCOMP levels returned to baseline 24–48 hours after the race, and for an ultra-
marathon sCOMP levels returned to baseline 6 days after the race.23, 33 Therefore, elevated
levels of sCOMP as a result of physical activity may indicate that this biomarker may be
useful for establishing the relationships between exercise and articular cartilage changes.
It has been reported that elite level athletes who participate in high impact sports for an
extended period of time may have more risk for developing primary OA.6, 25, 37 However,
there are no prospective, longitudinal studies investigating the effects of continuous, intense
physical activity over time on sCOMP. Therefore, to further investigate sCOMP as a
biomarker for cartilage damage induced by exercise, it is important to prospectively study
those who participate in high impact sports. Documentation of the stability of this marker
over the duration of an athletic season, rather than one bout of exercise, is needed for further
investigation of the effects of exercise on articular cartilage. In addition, patient reported
outcome instruments (PROS) are used to document self-reported function and knee related
symptoms. These can be used throughout the duration of the season to provide additional
information that might explain changes in sCOMP levels such as decrease in function, or an
increase in pain or knee related symptoms.
The primary purpose of this investigation was to document the stability of sCOMP in
collegiate soccer athletes during a spring soccer season. In addition, we aimed to document
patient reported outcomes assessing pain and function related to the knee joint using two
separate PROs. The hypotheses tested were that sCOMP levels and PRO scores would
remain stable over the duration of the spring soccer season. Finally, as a secondary analysis,
we aimed to determine if a relationship would be observed between changes in sCOMP
levels and PRO scores.
MATERIALS and METHODS
Design
A prospective case series study was employed to determine the stability of sCOMP over the
duration of a spring soccer season.
Population
A volunteer sample of 29 Division I NCAA soccer athletes (18 males, 11 females, age:
19.6±1.2 years, height:177.8±7.4cm, mass:73.8±10.2kg) participated in this research study.
Subjects were included if they were actively participating in the spring soccer season.
Subjects were excluded if they were not participating in soccer related activities. Informed
consent was obtained from the subjects participating in the study. This study was approved
by the Institutional Review Board at the University of Kentucky.
Procedure
Subjects reported for data collection at three time points (pre- (T1), mid- (T2) and post-
season (T3)) over the duration of their spring soccer season (February - May). Upon arrival,
each subject was asked to remain seated for 30 minutes. It is recommended that subjects
remain seated before serum collection in order for serum levels to return to baseline after
any moderate exercise such as walking to the data collection site.1, 31 During the 30 minutes
of rest the subjects were asked to complete two PROs (International Knee Documentation
Committee (IKDC) and Lysholm). Once the subjects had been seated for 30 minutes and
both PROs were completed, a maximum of 10 mL of blood was collected from the
antecubital fossa.
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The blood was immediately placed on ice and transported for separation. After clotting at
room temperature, sera were separated and stored in a −20° C freezer and eventually
transported into a −80° C freezer until assayed. Once all samples were collected, sCOMP
concentrations were determined using a commercial enzyme-linked immunosorbent assay
(Euro-Diagnostica, ALPCO, Salem, NH). Serum COMP values are expressed as ng/mL. The
average intra-assay coefficient of variance (CV) of all controls was 1%, the average intra-
assay CV of all samples was 1%, and the average inter-assay CV of all controls was 4%.
Patient Reported Outcomes
Subjects completed two PROs for this study, the IKDC and the Lysholm. These were used
to assess function and symptoms related to the knee, and were completed by each subject at
each time point. The IKDC is a valid and reliable PRO used to measure knee symptoms,
level of function, and sports activity in patients after knee injuries.15, 21 Higher scores
represent higher levels of function and fewer self-reported knee symptoms.15, 21 A change of
±9 points is required to indicate a clinically meaningful change in the patient’s knee
symptoms.21 The IKDC has acceptable internal consistency and test-retest reliability.20
The Lysholm knee scale measures eight condition specific domains for the knee.27, 38 These
domains include limping, use of supporting device, stair climbing, squatting, walking,
locking, instability, and pain.27, 38 The Lysholm is scored from 0 to 100, where a score of 95
to 100 is excellent, 89 to 94 is good, 65 to 83 is fair, and <65 is a poor.24 A minimal
detectable change (MDC) for the Lysholm is ±8.9 points.3 For patients with chondral and
ACL injuries, the Lysholm has acceptable internal consistency and test-retest reliability.3, 24
Statistical Analysis
Descriptive statistics (mean ± standard deviation (SD)) for sCOMP and PROs for each time
point are presented in the Table 1. The independent variables were time (T1, T2, T3) and sex
(male, female). The dependent variables were sCOMP values and scores on two PROs
(Lysholm, IKDC). Separate linear mixed models analyses were used to determine sex by
time interactions and differences in each of the dependent variables (sCOMP, IKDC,
Lysholm) for each of the time points (T1, T2, T3). Paired-sample t-tests were used to explain
significant interactions or main effects. Pearson correlations were employed to determine if
a relationship exists between changes in sCOMP levels and PRO scores for the 18 subjects
with sCOMP at each of the time points. Changes for T3 minus T2, T3 minus T1, and T2
minus T1 were calculated. Hedge’s g effect sizes17 with 95% confidence intervals (CI) were
calculated to examine the magnitude of change and associated variability over time for each
of the dependent variables. Calculated effect sizes were interpreted as weak if they were less
than 0.40, moderate if between 0.41 and 0.69, and strong if greater than 0.70.8 Alpha was set
a priori at p≤0.05. Statistical analyses were performed using IBM SPSS software, version
19.0 (Armonk, NY), and SAS version 19.2 (Cary, NC).
RESULTS
All injuries documented during the spring soccer season are listed in Appendix A and
surgeries that were treated or performed before the spring soccer season are listed in
Appendix B. Subjects were not excluded in this study if they had a history of injury or
surgery. All subjects who participated with a history of surgery were medically cleared to
participate in soccer activities as determined by an orthopaedic surgeon and a primary care
physician. No ongoing or resolving musculoskeletal injuries were recorded in subjects that
were enrolled into the study at the time of physical examination. All subjects that were
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treated for musculoskeletal injuries during the spring soccer season were included if they
were actively participating in soccer activities during the data collection sessions.
Figure 1 depicts the total number of sCOMP samples collected and processed for each of the
time points. Missing data points were attributed to a) the inability of the phlebotomist to
collect a sample, b) sample processing error, c) removal from the team, or d) severe knee
injury at time of data collection. Figure 1 also depicts the time lapse between each of the
data collection sessions. If sCOMP samples were not available for analysis, the PRO scores
for those subjects remained in the analysis for each of the time points.
Serum COMP Values
Descriptive statistics for each of the time points can be found in the Table. When all 29
subjects were included in the data analysis, there was no significant sex by time interaction
for sCOMP (p=0.44) or significant effect for sex (p=0.09). There was a significant effect of
time on sCOMP levels (p<0.001), with significant increases between T1-T2 (p<0.001), T1-
T3 (p=0.002), but not for T2-T3 (p=0.08). Calculated Hedge’s g effect sizes and 95% CIs for
sCOMP were 1.0 (CI: 0.4, 1.6) for T1 vs T2 and 0.6 (CI: 0.02, 1.2) for T1 vs T3. The effect
sizes for T1 vs T2 was interpreted as strong and the effect size for T1 vs T3 was interpreted
as moderate, and the associated 95% CI for both effect sizes do not encompass zero.
In addition, we performed a linear mixed model for the 18 athletes for which there were data
for each of the time points. When the 18 subjects with all data points in the data analysis,
there was no significant sex by time interaction for sCOMP (p=0.70). There was a
significant effect for sex (p=0.03). There was a significant effect for time on sCOMP levels
(p<0.001), with significant increases between T1-T2 (p<0.001), T1-T3 (p=0.005), but not for
T2-T3 (p=0.14).
Finally, we calculated means (±SDs) for four different groups: 1) all 29 athletes who
participated, 2) athletes with a documented history of injury or surgery, 3) athletes who were
treated for an injury during the soccer season, and 4) athletes with no documented injury
during the spring soccer season or surgery history (Figure 2). It must be noted that it is
possible for athletes to be in group 2 and group 3 for this analysis.
sCOMP Minimal Detectable Change
We calculated minimal detectable change (MDC) values using intersession reliability via an
intraclass correlation coefficient (ICC) mixed model (single measure), and standard error of
measurement (SEM). A total of 18 subjects had sCOMP values for all three data time points
and these values were used to calculate MDC value. The MDC value was calculated with a
95% level of confidence using the formula SEM * 1.96 * √3.2, 41 Single measure
intersession reliability over the three collection time points was ICC(2,1) =0.61
(SEM=136.9ng/mL). The MDC value for sCOMP over these three data points was 464.6ng/
mL.
Patient Reported Outcomes
Descriptive statistics for each of the PROs can be found in Table 1. There was no significant
sex by time interaction for either the Lysholm (p=0.52) or the IKDC (p=0.17). There was no
significant effect for sex for either the Lysholm (p=0.09) or the IKDC (p=0.23). A
significant effect for time was noted for the Lysholm (p=0.03), with significant increases
between T1-T3 (p=0.03), and T2-T3 (p=0.06). A significant effect for time was noted for the
IKDC (p=0.02), with significant increases between T1-T3 (p=0.02) and T2-T3 (p=0.04).
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Calculated effect sizes for the IKDC were 0.1 (CI: −0.4, 0.6) for T1 vs T2 and 0.5 (CI:−0.1,
1.1) for T1 vs T3 with one effect size interpreted as weak and one effect size interpreted as
moderate. For the Lysholm, the effect sizes were −0.1 (CI: −0.6, 0.5) for T1 vs T2 and 0.4
(CI: −0.2, 1.0) for T1 vs T3, with one effect size interpreted as weak and one effect size
interpreted as moderate. However, caution must be used when interpreting these results as
for each effect size, the 95% CIs did encompass zero.
Relationship between changes in sCOMP levels and PRO scores
There were no significant relationships between changes in sCOMP levels and PRO scores
when T2 and T1 were compared. The relationships between change in sCOMP levels and
IKDC and Lysholm scores were r=0.3 (p=0.2) and r=0.2 (p=0.4), respectively. There was a
significant positive relationship between changes in sCOMP levels and IKDC scores (r=0.5,
p=0.03), and sCOMP levels and Lysholm scores (r=0.5, p=0.05) between the T3 and T2 time
points. Finally, there was no relationship between sCOMP levels and IKDC (r=0.1, p=0.7)
or the Lysholm (r= 0.08, p=0.7) for changes calculated from T3 to T1.
DISCUSSION
The purpose of this study was to document the stability of sCOMP levels and PRO scores in
collegiate soccer athletes at three time points during a competitive athletic season. Serum
COMP levels and PRO scores increased over the duration of an athletic season. It was also
demonstrated that the differences between the time points did not exceed the intersession
MDC value of 464.6ng/mL reinforcing that the changes in our measures, while important to
note, may not have been clinically different.
There are few published studies that report baseline levels for young, healthy athletes or
patients.26, 36 Previously reported levels of sCOMP for six healthy athletes with no history
of joint disease or joint injury ages 30±9 was 47μg/mL with a range from 10–109μg/mL.26
Additionally, sCOMP baseline levels using healthy blood donors ages 20–65, and healthy
children ages 1–20, were reported to be 11.3μg/mL and 10.3μg/mL, respectively.36 The
baseline levels for the cohort in this study, who had a history of injury or surgery was 1482.9
ng/mL. When interpreting sCOMP results, it is important to realize inter-study variation
may be due to several other factors including the ELISA utilized, age, BMI, race, and
previous surgical intervention.7, 22 We believe it is important for authors to report these
demographics to allow for proper interpretation of sCOMP data, particularly in athletic
populations who are likely to have had previous musculoskeletal injuries.
This is the first study to report intersession MDC values for sCOMP levels in a physically
active population over the duration of an athletic season. Based on our findings, an MDC
value of greater than 464.6ng/mL would be necessary to imply a clinical change versus
being considered normal variability. In addition, inter- and intraday MDC values for a
physically active cohort with no history of lower extremity surgery have been calculated in a
previous investigation.18 These results indicated an interday value of 292 ng/mL and an
intraday value of 320 ng/mL are required to identify changes that exceed the variability of
the marker.18 It appears that the MDC value of 464.6 ng/mL for these collegiate level
athletes is higher than the MDC values that were calculated for a physically active cohort
with no history of lower extremity surgery.18 These differences may be real, as subjects with
a history of surgery were included in the present study but not in the previous
investigation.18 In addition, the differences in MDC values may also exist because of the
extended time frame of data collection. The MDC value calculated for this study spanned
several weeks of time, where the previous investigation were calculated for within and
between day differences.18 Recent literature has hypothesized the use of sCOMP as a
biomarker to elucidate the effects of acute articular cartilage injury and the development of
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preclinical posttraumatic osteoarthritis.10 The reported MDC values may be beneficial in
future investigations and provide a comparison to determine meaningful changes associated
with this measure.
This is the first study to report changes in sCOMP levels over the duration of an athletic
season. Previous investigations have reported changes in sCOMP levels following single
bouts of activity.23, 31–34 The results of this study indicate a statistical difference in the
increase in sCOMP levels between T1 and T2 p=0.001), and T1 and T3 (p=0.002). In
addition, there was a trend for a statistically significant decrease in sCOMP levels from T2
and T3 (p=0.08). However, based on the calculated MDC value of 464.6 ng/mL, differences
of 241 ng/mL for T1-T2, 142 ng/mL for T1-T3 and 99 ng/mLfor T2-T3 are not clinically
significant as they do not exceed the variability associated with the measure.
Additionally, we performed a secondary analysis of only those subjects for which we had
serum samples at all three time points. We identified statistically significant differences
between each of the time points, similar to the analysis of all subjects (n=29). However,
when the calculated MDC value is employed, none of the differences between these time
points were clinically meaningful, T1-T2= 205 ng/mL, T1-T3= 137 ng/mL, and T2-T3= 68
ng/mL. Furthermore, when the athletes were grouped according to whether they were treated
for an injury during the spring soccer season (Appendix A), had a previous history of injury
or surgery (Appendix B), or those subjects without injury during the spring soccer season or
history or surgery, we noticed similar patterns of change between each time point.
Specifically, upon visual analysis there was a change when baseline values were compared
with mid season and postseason however, the mean and standard deviations between groups
overlap signifying there likely was no difference between groups (Figure 2). While the
individuals with an injury that were treated during the spring season did not decrease as
much as the other groups at T3, this can be attributed to the time of injury from serum
collection. It may be that the athletes that were included in the ‘treated for an injury during
the spring soccer season’ group sustained injuries in the last half of the season and this
caused their levels to remain elevated.
At this time it is not known whether changes after single bouts of exercise are either
indicative of an increase in cartilage matrix turnover or cartilage damage.1, 23, 33 The current
findings, while not clinically significant, demonstrate that there are increases in sCOMP
levels over the duration of an athletic season, likely attributed to the total participation or
intensity of exercise. However, at this time we are unable to speculate whether these
fluctuations were related to an increase in cartilage matrix turnover or matrix degradation. In
addition, we are unable to determine the longitudinal effects of these fluctuations on overall
articular cartilage health. Finally, we hypothesize there was a trend for decreasing sCOMP
levels from T2-T3 due to a decrease in the amount of participation during the final four
weeks of the season. Total time of participation data is not available to support this
speculation; however, we do know that as the spring soccer season came to an end, the
athletes participated in fewer practice sessions and games. Based on these results, future
research studies are needed to investigate the influence participation on sCOMP levels in a
physically active cohort.
The current findings indicate a statistical difference between time points for the IKDC and
Lysholm. While these differences are important, and documentation of change due to
normal physical activity is important when employing PROs, these differences should be
interpreted with caution, as they were not clinically significant based on previously reported
MDC values. It has been reported that a change of ±9 points for the IKDC, and ±8.9 points
for the Lysholm indicate a significant change in patient’s knee symptoms.3, 21 For the
IKDC, a 5.1 point difference between T1 (89.7±12.4) and T3 (94.8±6.0) and a 4 point
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difference between T2 (90.8±8.8) and T3 (94.8±6.0) are not large enough to indicate a
clinically significant change in a subject’s knee symptoms. For the Lysholm, a 2.4 point
difference between scores of T1 (92.4±8.4) and T3 (96.3±7.1) and a 4 point difference
between T2 (92.3±10) and T3 (96.3±7.1) are also not sufficiently large to indicate clinically
significant changes in the subject’s knee symptoms. Furthermore, recent literature has
reported normative data for the Lysholm knee score in patients with normal knees.4 The
average Lysholm score was 94 (range 43–100) for uninjured participants.4 The current data
are representative of this score, with the average for each of the time points ranging from 92
to 96. These PRO scores show that these athletes were functioning at a normal level and
reported near normal joint health throughout the duration of the season.
LIMITATIONS
The present study is not without limitations. First, subjects that participated in the study
were not excluded based on medical history. Subjects with a history of injury, including
anterior cruciate ligament knee reconstruction (ACLR), were included in our study. Since
the aim was to determine the stability of sCOMP over time, exclusion of patients with a
previous history of severe knee injury or surgery was not required. Additionally, the injury
and surgery history data were collected retrospectively. Medical records were reviewed for
previous surgical or injury history. In addition, medical records were retrospectively
reviewed to obtain data regarding injuries that were treated during the spring soccer season.
Furthermore, both PROs employed in this study were specific to the knee joint. Serum
COMP is not specific to cartilage degradation at the knee joint. Therefore, the use of PROs
for other joints, such as the Foot and Ankle Ability Measurement (FAAM)28 or the
Disabilities of the Arm, Shoulder and Hand (DASH )19 could have been employed to
determine self-reported function for these joints. Finally, participation in activities outside of
soccer practice and soccer associated activities such as lifting and running were not
controlled for potential confounding effects.
CONCLUSION
The present findings indicate that sCOMP levels do change over duration of a soccer season;
however, the difference between each of the separate time points was less than the
calculated intersession MDC value of 464.6ng/mL. These results likely imply that the
effects of intense, continuous physical activity resulted in an increase in cartilage turnover
identified as increased levels of sCOMP; however, it is unclear whether this process had a
negative influence on overall joint health. Future research investigations are warranted to
further determine the relationship between these increased levels in sCOMP over the
duration of an athletic season, cartilage degradation, and a possible connection with primary
OA development in athletes who participate in continuous, intense physical activity.
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Flow chart depicting subject participation, data loss, and time between serum cartilage
oligomeric matrix protein data collection sessions.
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Serum COMP values (±SD) for 1) all 29 athletes that participated, 2) athletes with a
documented history of injury or surgery, 3) athletes who were treated for an injury during
the soccer season, and 4) athletes with no documented injury during the spring soccer season
or surgery history.
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Table 1
Serum cartilage oligomeric matrix protein (sCOMP) levels and patient reported outcome scores (Lysholm and
International Knee Documentation Committee (IKDC)) for each of the time points (pre-season (T1), mid-
season (T2) and post-season (T3)).
Dependent Variable (Mean±SD)* Pre-season (T1) Mid-season (T2) Post-season (T3)
sCOMP (ng/mL) 1482.9±217.9a,b 1723.5±257.9 1624.7±231.6
Lysholm 93.1±8.1a 92.3±10a 96.3±7.1
IKDC 89.7±12.4a 90.8±8.8a 94.8±6.0
*
Differences are significant at p≤0.05.
a
Significantly different from T3.
b
Significantly different from T2.
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